Regulation of human intestinal T-cell responses by type 1 interferon-STAT1 signaling is disrupted in inflammatory bowel disease

Mucosal Immunology

Volumn 10, Issue 1, 2017, Pages 184-193

  Giles, E M ^a,b   Sanders, T J ^c   McCarthy, N E ^a   Lung, J ^a   Pathak, M ^a   Macdonald, T T ^a   Lindsay, J O ^a   Stagg, A J ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MONASH CHILDREN S HOSPITAL   (Australia)

^c UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA INTERFERON; INTERFERON; INTERLEUKIN 10; STAT1 PROTEIN; BLOCKING ANTIBODY; GAMMA INTERFERON;

ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; COLON TISSUE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IN VITRO STUDY; INFLAMMATORY BOWEL DISEASE; INTESTINE TISSUE; ISG GENE; LYMPHOCYTE FUNCTION; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE SUBPOPULATION; TISSUE CULTURE; UPREGULATION; ADOLESCENT; ANIMAL; CELL CULTURE; CELL DIFFERENTIATION; CHILD; COLON; FEMALE; IMMUNOLOGY; IMMUNOMODULATION; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MOUSE; PHOSPHORYLATION; REGULATORY T LYMPHOCYTE;

ADOLESCENT; ANIMALS; ANTIBODIES, BLOCKING; CELL DIFFERENTIATION; CELLS, CULTURED; CHILD; COLON; FEMALE; HUMANS; IMMUNOMODULATION; INFLAMMATORY BOWEL DISEASES; INTERFERON-BETA; INTERFERON-GAMMA; INTERLEUKIN-10; LYMPHOCYTE ACTIVATION; MALE; MICE; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STAT1 TRANSCRIPTION FACTOR; T-LYMPHOCYTES, REGULATORY;

EID: 85011044796     PISSN: 19330219     EISSN: 19353456     Source Type: Journal    
DOI: 10.1038/mi.2016.44     Document Type: Article

References (38)

1. Neurath, M.F. Cytokines in inflammatory bowel disease. Nat. Rev. Immunol. 14, 329-342 (2014).
2. O'Shea, J. &Paul, W. Mechanisms underlying lineage commitment and plasticity of helper CD4+ T cells. Science 327, 1098-1102 (2010).
3. Strober, W. &Fuss, I.J. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology 140, 1756-1767 (2011).
4. Laouar, A. et al. CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. Nat. Immunol. 6, 698-706 (2005).
5. Tough, D.F. Modulation of T-cell function by type I interferon. Immunol. Cell Biol. 90, 492-497 (2012).
6. Gough, D.J., Messina, N.L., Clarke, C.J., Johnstone, R.W. &Levy, D.E. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 36, 166-174 (2012).
7. Nguyen, K.B. et al. Critical role for STAT4 activation by type 1 interferons in the interferon-gamma response to viral infection. Science 297, 2063-2066 (2002).
8. Teijaro, J.R. et al. Persistent LCMV infection is controlled by blockade of type I interferon signaling. Science 340, 207-211 (2013).
9. Wilson, E.B. et al. Blockade of chronic type I interferon signaling to control persistent LCMV infection. Science 340, 202-207 (2013).
10. Odorizzi, P.M. &Wherry, E.J. Immunology. An interferon paradox. Science 340, 155-156 (2013).
11. Cho, H. &Kelsall, B.L. The role of type I interferons in intestinal infection, homeostasis, and inflammation. Immunol. Rev. 260, 145-167 (2014).
12. McFarland, A.P. et al. Localized delivery of interferon-b by Lactobacillus exacerbates experimental colitis. PLoS One 6, e16967 (2011).
13. Abe, K. et al. Conventional dendritic cells regulate the outcome of colonic inflammation independently of T cells. Proc. Natl. Acad. Sci. USA 104, 17022-17027 (2007).
14. Bleich, A. et al. CpG motifs of bacterial DNA exert protective effects in mouse models of IBD by antigen-independent tolerance induction. Gastroenterology 136, 278-287 (2009).
15. Kole, A. et al. Type I IFNs regulate effector and regulatory T cell accumulation and anti-inflammatory cytokine production during T cellmediated colitis. J. Immunol. 191, 2771-2779 (2013).
16. Lee, S.E. et al. Type I interferons maintain foxp3 expression and T-regulatory cell functions under inflammatory conditions in mice. Gastroenterology 143, 145-154 (2012).
17. Radulovic, K. et al. CD69 regulates type I IFN-induced tolerogenic signals to mucosal CD4 T cells that attenuate their colitogenic potential. J. Immunol. 188, 2001-2013 (2012).
18. Axtell, R.C. et al. T helper type 1 and 17 cells determine efficacy of interferon-beta in multiple sclerosis and experimental encephalomyelitis. Nat. Med. 16, 406-412 (2010).
19. Jostins, L. et al. Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491, 119-124 (2012).
20. Seow, C.H., Benchimol, E.I., Griffiths, A.M. &Steinhart, A.H. Type I interferons for induction of remission in ulcerative colitis. Cochrane Database Syst. Rev. CD006790, 16 (2008).
21. Teles, R.M. et al. Type I interferon suppresses type II interferon-triggered human anti-mycobacterial responses. Science 339, 1448-1453 (2013).
22. Afkarian, M. et al. T-bet is a STAT1-induced regulator of IL-12R expression in naïve CD4+ T cells. Nat. Immunol. 3, 549-557 (2002).
23. Neurath, M.F. et al. The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn's disease. J. Exp. Med. 195, 1129-1143 (2002).
24. Kelsen, J. et al. FoxP3(+)CD4(+)CD25(+) T cells with regulatory properties can be cultured from colonic mucosa of patients with Crohn's disease. Clin. Exp. Immunol. 141, 549-557 (2005).
25. Hofmann, C. et al. T cell-dependent protective effects of CpG motifs of bacterial DNA in experimental colitis are mediated by CD11c+ dendritic cells. Gut 59, 1347-1354 (2010).
26. Wang, J., Ioan-Facsinay, A., van der Voort, E.I., Huizinga, T.W. &Toes, R.E. Transient expression of FOXP3 in human activated nonregulatory CD4+ T cells. Eur. J. Immunol. 37, 129-138 (2007).
27. Metidji, A. et al. IFN-a/b receptor signaling promotes regulatory T cell development and function under stress conditions. J. Immunol. 194, 4265-4276 (2015).
28. MacDermott, R.P., Bragdon, M.J., Kodner, I.J. &Bertovich, M.J. Deficient cell-mediated cytotoxicity and hyporesponsiveness to interferon and mitogenic lectin activation by inflammatory bowel disease peripheral blood and intestinal mononuclear cells. Gastroenterology 90, 6-11 (1986).
29. Mudter, J. et al. Activation pattern of signal transducers and activators of transcription (STAT) factors in inflammatory bowel diseases. Am. J. Gastroenterol. 100, 64-72 (2005).
30. Lovato, P. et al. Constitutive STAT3 activation in intestinal T cells from patients with Crohn's disease. J. Biol. Chem. 278, 16777-16781 (2003).
31. Horino, J. et al. Suppressor of cytokine signaling-1 ameliorates dextran sulfate sodium-induced colitis in mice. Int. Immunol. 20, 753-762 (2008).
32. Palmer, D.C. &Restifo, N.P. Suppressors of cytokine signaling (SOCS) in T cell differentiation, maturation, and function. Trends Immunol. 30, 592-602 (2009).
33. Musch, E. et al. Topical treatment with the Toll-like receptor agonist DIMS0150 has potential for lasting relief of symptoms in patients with chronic active ulcerative colitis by restoring glucocorticoid sensitivity. Inflamm. Bowel Dis. 19, 283-292 (2013).
34. Norman, J.M. et al. Disease-specific alterations in the enteric virome in inflammatory bowel disease. Cell 160, 447-460 (2015).
35. Nguyen,K.B. et al. Interferonalpha/beta-mediated inhibition and promotion of interferon gamma: STAT1 resolves a paradox. Nat. Immunol. 1, 70-76 (2000).
36. Mahida, Y.R. et al. Migration of human intestinal lamina propria lymphocytes, macrophages and eosinophils following the loss of surface epithelial cells. Clin. Exp. Immunol. 109, 377-386 (1997).
37. Hart, A. et al. Characteristics of intestinal dendritic cells in inflammatory bowel diseases. Gastroenterology 129, 50-65 (2005).
38. Bell, S.J. et al. Migration and maturation of human colonic dendritic cells. J. Immunol. 166, 4958-4967 (2001).